1
|
Chiavellini P, Lehmann M, Gallardo MD, Mallat MC, Pasquini DC, Zoller JA, Gordevicius J, Girard M, Lacunza E, Herenu CB, Horvath S, Goya RG. Young Plasma Rejuvenates Blood DNA Methylation Profile, Extends Mean Lifespan, and Improves Physical Appearance in Old Rats. J Gerontol A Biol Sci Med Sci 2024; 79:glae071. [PMID: 38430547 PMCID: PMC11020299 DOI: 10.1093/gerona/glae071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Indexed: 03/04/2024] Open
Abstract
There is converging evidence that young blood conveys cells, vesicles, and molecules able to revitalize function and restore organ integrity in old individuals. We assessed the effects of young plasma on the lifespan, epigenetic age, and healthspan of old female rats. Beginning at 25.6 months of age, a group of 9 rats (group T) was intraperitoneally injected with plasma from young rats until their natural death. A group of 8 control rats of the same age received no treatment (group C). Blood samples were collected every other week. Survival curves showed that from age 26 to 30 months, none of the group T animals died, whereas the survival curve of group C rats began to decline at age 26 months. Blood DNAm age versus chronological age showed that DNAm age in young animals increased faster than chronological age, then slowed down, entering a plateau after 27 months. The DNAm age of the treated rats fell below the DNAm age of controls and, in numerical terms, remained consistently lower until natural death. When rats were grouped according to the similarities in their differential blood DNA methylation profile, samples from the treated and control rats clustered in separate groups. Analysis of promoter differential methylation in genes involved in systemic regulatory activities revealed specific GO term enrichment related to the insulin-like factors pathways as well as to cytokines and chemokines associated with immune and homeostatic functions. We conclude that young plasma therapy may constitute a natural, noninvasive intervention for epigenetic rejuvenation and health enhancement.
Collapse
|
2
|
Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, van Pesch V, Van Wijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Triviño, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ 2024; 27:109-125. [PMID: 38085684 DOI: 10.1080/13696998.2023.2293379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 12/07/2023] [Indexed: 12/23/2023]
Abstract
AIM To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a UK National Health Service perspective, of natalizumab versus fingolimod in patients with rapidly evolving severe relapsing-remitting multiple sclerosis (RES-RRMS). METHODS Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD). Matched cohorts were selected by 3-way multinomial propensity score matching, and the annualized relapse rate (ARR) and 6-month-confirmed disability worsening (CDW6M) and improvement (CDI6M) were compared between treatment groups. Comparative effectiveness results were used in a cost-effectiveness model comparing natalizumab and fingolimod, using an established Markov structure over a lifetime horizon with health states based on the Expanded Disability Status Scale. Additional model data sources included the UK MS Survey 2015, published literature, and publicly available sources. RESULTS In the comparative effectiveness analysis, we found a significantly lower ARR for patients starting natalizumab compared with fingolimod (rate ratio [RR] = 0.65; 95% confidence interval [CI], 0.57-0.73) or BRACETD (RR = 0.46; 95% CI, 0.42-0.53). Similarly, CDI6M was higher for patients starting natalizumab compared with fingolimod (hazard ratio [HR] = 1.25; 95% CI, 1.01-1.55) and BRACETD (HR = 1.46; 95% CI, 1.16-1.85). In patients starting fingolimod, we found a lower ARR (RR = 0.72; 95% CI, 0.65-0.80) compared with starting BRACETD, but no difference in CDI6M (HR = 1.17; 95% CI, 0.91-1.50). Differences in CDW6M were not found between the treatment groups. In the base-case cost-effectiveness analysis, natalizumab dominated fingolimod (0.302 higher quality-adjusted life-years [QALYs] and £17,141 lower predicted lifetime costs). Similar cost-effectiveness results were observed across sensitivity analyses. CONCLUSIONS This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.
Collapse
|
3
|
Hauser S, Lazarevic V, Tournoud M, Ruppé E, Santiago Allexant E, Guigon G, Schicklin S, Lanet V, Girard M, Mirande C, Gervasi G, Schrenzel J. A metagenomics method for the quantitative detection of bacterial pathogens causing hospital-associated and ventilator-associated pneumonia. Microbiol Spectr 2023; 11:e0129423. [PMID: 37889000 PMCID: PMC10715005 DOI: 10.1128/spectrum.01294-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Accepted: 09/29/2023] [Indexed: 10/28/2023] Open
Abstract
IMPORTANCE The management of ventilator-associated pneumonia and hospital-acquired pneumonia requires rapid and accurate quantitative detection of the infecting pathogen. To this end, we propose a metagenomic sequencing assay that includes the use of an internal sample processing control for the quantitative detection of 20 relevant bacterial species from bronchoalveolar lavage samples.
Collapse
|
4
|
Naus S, Maasakkers JD, Gautam R, Omara M, Stikker R, Veenstra AK, Nathan B, Irakulis-Loitxate I, Guanter L, Pandey S, Girard M, Lorente A, Borsdorff T, Aben I. Assessing the Relative Importance of Satellite-Detected Methane Superemitters in Quantifying Total Emissions for Oil and Gas Production Areas in Algeria. ENVIRONMENTAL SCIENCE & TECHNOLOGY 2023; 57:19545-19556. [PMID: 37956986 DOI: 10.1021/acs.est.3c04746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2023]
Abstract
Methane emissions from oil and gas production provide an important contribution to global warming. We investigate 2020 emissions from the largest gas field in Algeria, Hassi R'Mel, and the oil-production-dominated area Hassi Messaoud. We use methane data from the high-resolution (20 m) Sentinel-2 instruments to identify and estimate emission time series for 11 superemitters (including 10 unlit flares). We integrate this information in a transport model inversion that uses methane data from the coarser (7 km × 5.5 km) but higher-precision TROPOMI instrument to estimate emissions from both the 11 superemitters (>1 t/h individually) and the remaining diffuse area source (not detected as point sources with Sentinel-2). Compared to a bottom-up inventory for 2019 that is aligned with UNFCCC-reported emissions, we find that 2020 emissions in Hassi R'Mel (0.16 [0.11-0.22] Tg/yr) are lower by 53 [24-73]%, and emissions in Hassi Messaoud (0.22 [0.13-0.28] Tg/yr) are higher by 79 [4-188]%. Our analysis indicates that a larger fraction of Algeria's methane emissions (∼75%) come from oil production than national reporting suggests (5%). Although in both regions the diffuse area source constitutes the majority of emissions, relatively few satellite-detected superemitters provide a significant contribution (24 [12-40]% in Hassi R'Mel; 49 [27-71]% in Hassi Messaoud), indicating that mitigation efforts should address both. Our synergistic use of Sentinel-2 and TROPOMI can produce a unique and detailed emission characterization of oil and gas production areas.
Collapse
|
5
|
Paquet A, Calvet B, Lacroix A, Girard M. Sensory Processing in Depression: Assessment and Intervention Perspective. Clin Psychol Psychother 2022; 29:1567-1579. [DOI: 10.1002/cpp.2785] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 08/02/2022] [Accepted: 08/30/2022] [Indexed: 11/08/2022]
|
6
|
Paquet A, Lacroix A, Calvet B, Girard M. Psychomotor semiology in depression: a standardized clinical psychomotor approach. BMC Psychiatry 2022; 22:474. [PMID: 35841086 PMCID: PMC9287955 DOI: 10.1186/s12888-022-04086-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 06/23/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Although psychomotor symptoms are associated with the clinical symptomatology of depression, they are rarely assessed and standardized clinical evaluation tools are lacking. Psychomotor retardation is sometimes assessed through direct patient observations by clinicians or through a clinical observation grid, in the absence of a standardized psychomotor assessment. In this pilot study, we evaluated the feasibility of standardized psychomotor examination of patients with major depressive disorder (MDD) and detailed a psychomotor semiology in these patients. METHODS We used a standardized psychomotor assessment to examine 25 patients with MDD and 25 age- and sex-matched healthy controls (HC) and compared their psychomotor profiles. Using standardized tests, we assessed muscle tone and posture, gross motor skills, perceptual-motor skills, and body image/organization. Clinical assessments of depressive symptoms (levels of psychomotor retardation, anxiety, and self-esteem) comprised this detailed psychomotor examination. RESULTS All participants were examined using the standardized psychomotor assessment. The main results of the psychomotor examination highlighted low body image of MDD participants (p < 0.001). Significant differences between groups were found in passive muscle tone, posture, emotional control, jumping, manual dexterity, walking, and praxis. Among these psychomotor variables, body image, passivity, jumping and rhythm scores predicted an MDD diagnosis. CONCLUSIONS Beyond the psychomotor retardation known to be present in MDD patients, this examination revealed an entire psychomotor symptomatology characterized by elevated muscle tone, poor body image associated with poor self-esteem, slowness in global motor skills and manual praxis, and poor rhythmic adaptation. In light of these results, we encourage clinicians to consider using a standardized tool to conduct detailed psychomotor examination of patients with depressive disorders. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT04031937 , 24/07/2019.
Collapse
|
7
|
Finkelstein N, Dayam RM, Law J, Goetgebuer R, Chao G, Abe KT, Sutton M, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Rymaszewski K, Milgrom R, Ganatra D, Batista NV, Girard M, Lau I, Law R, Cheung M, Rathod B, Kitaygorodsky J, Samson R, Hu Q, Haroon N, Inman R, Piguet V, Silverberg M, Grigras AC, Watts TH, Chandran V. POS1217 ANTI-TNF THERAPY FOR IMMUNE MEDIATED INFLAMMATORY DISEASES MAY BE ASSOCIATED WITH LOWER ANTIBODY LEVELS AND VIRUS NEUTRALIZATION EFFICACY FOLLOWING SARS-CoV-2 mRNA VACCINATION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe impact of immunosuppressants on COVID-19 vaccination response and durability in patients with immune-mediated inflammatory diseases (IMID) is yet to be fully characterized. Humoral response may be attenuated in these patients especially those on B cell depleting therapy and higher doses of corticosteroids, but data regarding other immunosuppressants are scarce.ObjectivesWe aimed to investigate antibody and T cell responses and durability to SARS-CoV-2 mRNA vaccines (BNT162b and/or mRNA 1273) in IMID patients on immunomodulatory maintenance therapy other than B-cell depleting therapy and corticosteroids.MethodsThis prospective observational cohort study examined the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with IMIDs (psoriatic arthritis, psoriasis, inflammatory bowel disease and rheumatoid arthritis) with or without maintenance immunosuppressive therapies (anti-TNF, methotrexate/azathioprine [MTX/AZA], anti-TNF + MTX/AZA, anti IL12/23, anti-IL-17, anti-IL23) compared to healthy controls. Automated ELISA for IgGs to spike trimer, spike receptor binding domain (RBD) and the nucleocapsid (NP) and T-cell release of 9 cytokines (IFNg, IL2, IL4, IL17A, TNF) and cytotoxic molecules (sFasL, GzmA, GzmB, Perforinin) in cell culture supernatants following stimulation with spike or NP peptide arrays were conducted at 4 time points: T1=pre vaccination, T2=median 26 days after dose 1, T3=median 16 days after dose 2 and T4=median 106 days after dose 2. Neutralization assays against four SARS-CoV-2 variants (wild type, delta, beta and gamma) were conducted at T3.ResultsWe followed 150 subjects: 26 healthy controls and 124 IMID patients: 9 untreated, 44 on anti-TNF, 16 on anti-TNF with MTX/AZA, 10 on anti-IL23, 28 on anti-IL12/23, 9 on anti-IL17, 8 on MTX/AZA (Table 1). Most patients mounted antibody and T cell responses with increases from dose 1 to dose 2 (100% seroconversion at T3) and some decline by T4, with variability within groups. Antibody levels and neutralization efficacy was lower in anti-TNFgroups (anti-TNF, anti-TNF + MTX/AZA) compared to controls and waned by T4 (Figure 1). T cell responses were not consistently different between groups. Pooled data showed a higher antibody response to mRNA-1273 compared to BNT162b.Table 1.Baseline characteristics of study participantsControluntreated IMIDAnti- TNFAnti- TNF +MTX/AZAAnti-IL-23Anti -IL-12/23Anti -IL-17MTX/AZAn=26n=9n=44n=16n=10n=28n=9n=8p-valueIMID*N/A IBD9301002704 Psoriasis1318122 PA0732172 AS0830010 RA1100011Age median years [IQR]36 [26-46]33 [27-41]38 [30-51]53 [44-59]48 [45-61]34 [28-47]49 [46-61]42 [31-55]<0.001^Sex male (%)16 (62)5 (56)18 (41)8 (50)5 (50)13 (46)6 (67)4 (50)0.772~BMImedian kg/m2 [IQR]25 [23-28]26 [22-27]22 [24-26]26 [24-28]27 [24-35]22 [21-24]32 [26-34]26[25-33]0.001^Vaccine interval median days [IQR]74 [35-84]54 [31-64]60 [45-69]64 [50-72]74 [35-84]62 [49-69]65 [52-75]58 [21-97]0.372^*multiple IMIDs per patient possibleFigure 1.Antibody responses (A) Anti spike and anti RBD IgG levels at indicated time points. Blue line represents median ratio in convalescent patients. The red line is the seropositivity threshold: the median antibody level of those that pass both a 1% false positive rate and show ≥3SD from the log means of the negative controls. (B) Relative ratio of RBD, spike and NP across time. Black and gray lines indicate median and mean values, respectively. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001ConclusionFollowing 2 doses of mRNA vaccination there is 100% seroconversion in IMID patients on maintenance therapy. Antibody levels and neutralization efficacy in anti-TNF group are lower than controls, and wane substantially by 3 months after dose 2. These findings highlight the need for third dose in patients undergoing treatment with anti-TNF therapy and continued monitoring of immunity in these patient groups, taking into consideration newer variants and additional vaccine doses.AcknowledgementsThis work was funded by a donation from Juan and Stefania Speck and by grants VR-1 172711, VS1-175545, FDN-143250, GA1- 177703 and GA2- 177716, from Canadian Institutes of Health Research and COVID Immunity task force and by Sinai Health FoundationDisclosure of InterestsNaomi Finkelstein: None declared, Roya M. Dayam: None declared, Jaclyn Law: None declared, Rogier Goetgebuer: None declared, Gary Chao: None declared, Kento T. Abe: None declared, Mitchell Sutton: None declared, Joanne M. Stempak: None declared, Daniel Pereira: None declared, David Croitoru: None declared, Lily Acheampong: None declared, Saima Rizwan: None declared, Klaudia Rymaszewski: None declared, Raquel Milgrom: None declared, Darshini Ganatra: None declared, Nathalia V. Batista: None declared, Melanie Girard: None declared, Irene Lau: None declared, Ryan Law: None declared, Michelle Cheung: None declared, Bhavisha Rathod: None declared, Julia Kitaygorodsky: None declared, Reuben Samson: None declared, Queenie Hu: None declared, Nigil Haroon: None declared, Robert Inman Consultant of: AbbVie, Janssen, Lilly, Novartis., Grant/research support from: AbbVie, Novartis, Vincent Piguet Consultant of: AbbVie, Almirall, Celgene, Janssen, Kyowa Kirin Co. Ltd, LEO Pharma,Novartis, Pfizer, Sanofi, UCB, and Union Therapeutic, Grant/research support from: Unrestricted educational grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, L’Oréal, NAOS, Novartis, Pfizer, Pierre-Fabre, Sandoz, and Sanofi, Mark Silverberg Speakers bureau: AbbVie, Janssen, Takeda, Pfizer, Gilead and Amgen, Consultant of: AbbVie, Janssen, Takeda, Pfizer, Gilead and Amgen, Grant/research support from: AbbVie, Janssen, Takeda, Pfizer, Gilead and Amgen, Anne-Claude Grigras: None declared, Tania H. Watts: None declared, Vinod Chandran Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Amgen, Eli-Lilly.
Collapse
|
8
|
Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Med Res Methodol 2022; 22:155. [PMID: 35637426 PMCID: PMC9150358 DOI: 10.1186/s12874-022-01623-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 04/25/2022] [Indexed: 11/18/2022] Open
Abstract
Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled. Supplementary Information The online version contains supplementary material available at 10.1186/s12874-022-01623-8.
Collapse
|
9
|
Bahans C, Leymarie S, Malauzat D, Girard M, Demiot C. Ethical considerations of the dynamics of clinical trials in an epidemic context: Studies on COVID-19. ACTA ACUST UNITED AC 2020; 16:100621. [PMID: 33349794 PMCID: PMC7744003 DOI: 10.1016/j.jemep.2020.100621] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 12/11/2020] [Indexed: 01/27/2023]
Abstract
The COVID-19 epidemic has led to the intense mobilization of all health professionals, including those involved in research. From the very beginning, research ethics committees (RECs) have been called upon and mobilized to carry out the scientific and ethical evaluations of research projects to achieve a sound analysis of their risk/benefit balance. The aim of this article is to present an ethical reflection on the challenges and consequences of the fast-track procedure for the evaluation of COVID-19 research projects in the context of a public health emergency. Indeed, a large number of protocols of reduced rigor were hastily prepared without collaboration between researchers and in the absence of national regulation. As a result, a number of ethical dilemmas have emerged concerning the opposing needs of pragmatism imposed by the emergency context and the ethical principles that should govern the conduct of research. Moreover, the dispersion of these individual projects, aggravated by excessive media coverage of specific treatments, has resulted in a weakened impact of the research in the epidemic context. This article provides suggestions for the ethical management of ongoing and upcoming research, giving RECs the opportunity to adapt their evaluations to avoid allowing the pragmatism of the emergency context to subvert the inviolability of the epistemological and ethical principles of research on humans. This reflection may strengthen the ethical basis for the formulation of their decisions.
Collapse
|
10
|
Brignon L, Arnal M, Jésus P, Girard M, Clément J, Sazerat P, Nubukpo P, Charles E. Dépistage des troubles du comportement alimentaire à l’aide du SCOFF-F chez les sportifs de haut niveau en Nouvelle-Aquitaine. NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Girard M, Hu D, Pradervand N, Neuenschwander S, Bee G. Chestnut extract but not sodium salicylate decreases the severity of diarrhea and enterotoxigenic Escherichia coli F4 shedding in artificially infected piglets. PLoS One 2020; 15:e0214267. [PMID: 32106264 PMCID: PMC7046202 DOI: 10.1371/journal.pone.0214267] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 01/16/2020] [Indexed: 01/16/2023] Open
Abstract
The development of alternatives to antibiotics is crucial to limiting the incidence of antimicrobial resistance, especially in prophylactic and metaphylactic use to control post-weaning diarrhea (PWD). Feed additives, including bioactive compounds, could be a promising alternative. This study aimed to test two bioactive compounds, sodium salicylate (SA) and a chestnut extract (CE) containing hydrolysable tannins, on the occurrence of PWD. At weaning, 72 piglets were assigned to four treatments that combined two factors: CE supplementation (with 2% of CE (CE+) or without (CE-)) and SA supplementation (with 35 mg/kg BW of SA (SA+) or without (SA-)). Then, 4 days after weaning, all piglets were infected with a suspension at 108 CFU/ml of enterotoxigenic Escherichia coli (ETEC F4ac). Each piglet had free access to an electrolyte solution containing, or not, SA. This SA supplementation was administered for 5 days (i.e., from the day of infection (day 0) to 4 days post-infection (day 4). During the 2 weeks post-infection, supplementation with SA had no effect (P > 0.05) on growth performances nor on fecal scores. A significant SA × time interaction (P < 0.01) for fecal scores and the percentage of diarrhea indicated that piglets with SA did not recover faster and did have a second episode of diarrhea. In contrast to SA treatment, inclusion of CE increased (P < 0.05) growth performances and feed intake. In the first week post-infection, CE decreased (P < 0.001) the overall fecal scores, the percentage of piglets with diarrhea, the days in diarrhea, and ETEC shedding in the feces. There was a SA×CE interaction (P < 0.05) for ETEC shedding, suggesting a negative effect of combining SA with CE. This study highlighted that, in contrast to SA, CE could represent a promising alternative to antibiotics immediately after weaning for improving growth performance and reducing PWD.
Collapse
|
12
|
Girard M, Arguin G, Longpré J, Sarret P, Gendron F. A287 CARACTÉRISATION DE LA SIGNALISATION P2Y 6 DANS LA MIGRATION CELLULAIRE . J Can Assoc Gastroenterol 2019. [DOI: 10.1093/jcag/gwz006.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Adamczyk L, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Alford J, Anson CD, Aparin A, Arkhipkin D, Aschenauer EC, Averichev GS, Banerjee A, Beavis DR, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bichsel H, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Borowski W, Bouchet J, Brandin AV, Brovko SG, Bültmann S, Bunzarov I, Burton TP, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Cendejas R, Cervantes MC, Chaloupka P, Chang Z, Chattopadhyay S, Chen HF, Chen JH, Chen L, Cheng J, Cherney M, Chikanian A, Christie W, Chwastowski J, Codrington MJM, Contin G, Cramer JG, Crawford HJ, Cui X, Das S, Davila Leyva A, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, Derradi de Souza R, Dhamija S, di Ruzza B, Didenko L, Dilks C, Ding F, Djawotho P, Dong X, Drachenberg JL, Draper JE, Du CM, Dunkelberger LE, Dunlop JC, Efimov LG, Engelage J, Engle KS, Eppley G, Eun L, Evdokimov O, Eyser O, Fatemi R, Fazio S, Fedorisin J, Filip P, Finch E, Fisyak Y, Flores CE, Gagliardi CA, Gangadharan DR, Garand D, Geurts F, Gibson A, Girard M, Gliske S, Greiner L, Grosnick D, Gunarathne DS, Guo Y, Gupta A, Gupta S, Guryn W, Haag B, Hamed A, Han LX, Haque R, Harris JW, Heppelmann S, Hirsch A, Hoffmann GW, Hofman DJ, Horvat S, Huang B, Huang HZ, Huang X, Huck P, Humanic TJ, Igo G, Jacobs WW, Jang H, Judd EG, Kabana S, Kalinkin D, Kang K, Kauder K, Ke HW, Keane D, Kechechyan A, Kesich A, Khan ZH, Kikola DP, Kisel I, Kisiel A, Koetke DD, Kollegger T, Konzer J, Koralt I, Kotchenda L, Kraishan AF, Kravtsov P, Krueger K, Kulakov I, Kumar L, Kycia RA, Lamont MAC, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, LeVine MJ, Li C, Li W, Li X, Li X, Li Y, Li ZM, Lisa MA, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Ma GL, Ma YG, Madagodagettige Don DMMD, Mahapatra DP, Majka R, Margetis S, Markert C, Masui H, Matis HS, McDonald D, McShane TS, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nandi BK, Nasim M, Nayak TK, Nelson JM, Nigmatkulov G, Nogach LV, Noh SY, Novak J, Nurushev SB, Odyniec G, Ogawa A, Oh K, Ohlson A, Okorokov V, Oldag EW, Olvitt DL, Pachr M, Page BS, Pal SK, Pan YX, Pandit Y, Panebratsev Y, Pawlak T, Pawlik B, Pei H, Perkins C, Peryt W, Pile P, Planinic M, Pluta J, Poljak N, Porter J, Poskanzer AM, Pruthi NK, Przybycien M, Pujahari PR, Putschke J, Qiu H, Quintero A, Ramachandran S, Raniwala R, Raniwala S, Ray RL, Riley CK, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ross JF, Roy A, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Sakrejda I, Salur S, Sandweiss J, Sangaline E, Sarkar A, Schambach J, Scharenberg RP, Schmah AM, Schmidke WB, Schmitz N, Seger J, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma B, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Singaraju RN, Skoby MJ, Smirnov D, Smirnov N, Solanki D, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stevens JR, Stock R, Strikhanov M, Stringfellow B, Sumbera M, Sun X, Sun XM, Sun Y, Sun Z, Surrow B, Svirida DN, Symons TJM, Szelezniak MA, Takahashi J, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Trzeciak BA, Tsai OD, Turnau J, Ullrich T, Underwood DG, Van Buren G, van Nieuwenhuizen G, Vandenbroucke M, Vanfossen JA, Varma R, Vasconcelos GMS, Vasiliev AN, Vertesi R, Videbæk F, Viyogi YP, Vokal S, Vossen A, Wada M, Wang F, Wang G, Wang H, Wang JS, Wang XL, Wang Y, Wang Y, Webb G, Webb JC, Westfall GD, Wieman H, Wissink SW, Witt R, Wu YF, Xiao Z, Xie W, Xin K, Xu H, Xu J, Xu N, Xu QH, Xu Y, Xu Z, Yan W, Yang C, Yang Y, Yang Y, Ye Z, Yepes P, Yi L, Yip K, Yoo IK, Yu N, Zawisza Y, Zbroszczyk H, Zha W, Zhang JB, Zhang JL, Zhang S, Zhang XP, Zhang Y, Zhang ZP, Zhao F, Zhao J, Zhong C, Zhu X, Zhu YH, Zoulkarneeva Y, Zyzak M. Erratum: Observation of D^{0} Meson Nuclear Modifications in Au+Au Collisions at sqrt[s_{NN}]=200 GeV [Phys. Rev. Lett. 113, 142301 (2014)]. PHYSICAL REVIEW LETTERS 2018; 121:229901. [PMID: 30547623 DOI: 10.1103/physrevlett.121.229901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Indexed: 06/09/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.113.142301.
Collapse
|
14
|
Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Eur J Neurol 2018; 26:363-370. [PMID: 30298572 DOI: 10.1111/ene.13824] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 10/04/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE Treatment options in primary progressive multiple sclerosis (PPMS) are scarce and, with the exception of ocrelizumab, anti-inflammatory agents have failed to show efficacy in ameliorating disability progression. The aim of this study was to investigate a potential effect of anti-inflammatory disease-modifying treatment on disability outcomes in PPMS. METHODS Using MSBase, a large, international, observational database, we identified patients with PPMS who were either never treated or treated with a disease-modifying agent. Propensity score matching was used to select subpopulations with similar baseline characteristics. Expanded Disability Status Scale (EDSS) outcomes were compared with an intention-to-treat and an as-treated approach in paired, pairwise-censored analyses. RESULTS Of the 1284 included patients, 533 were matched (treated, n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2-5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6-1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6-1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7-1.6, P = 0.69). CONCLUSION Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.
Collapse
|
15
|
Ramasamy A, Ng J, Foin N, Girard M, Dijkstra J, Zanchin T, Crake T, Torii R, Rakhit R, Serruys PW, Raber L, Baumbach A, Mathur A, Bourantas CV. P6496Advantages and limitations of the attenuation-compensated technique in assessing plaque and neointima morphology in optical coherence tomography. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Ajitanand NN, Alekseev I, Anderson DM, Aoyama R, Aparin A, Arkhipkin D, Aschenauer EC, Ashraf MU, Attri A, Averichev GS, Bai X, Bairathi V, Barish K, Behera A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandenburg JD, Brandin AV, Brown D, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Chakaberia I, Chaloupka P, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen JH, Chen X, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Debbe RR, Dedovich TG, Deng J, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Dunkelberger LE, Dunlop JC, Efimov LG, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Federicova P, Fedorisin J, Feng Z, Filip P, Finch E, Fisyak Y, Flores CE, Fujita J, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Grosnick D, Gunarathne DS, Guo Y, Gupta S, Gupta A, Guryn W, Hamad AI, Hamed A, Harlenderova A, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Hoffmann GW, Horvat S, Huang X, Huang HZ, Huang T, Huang B, Humanic TJ, Huo P, Igo G, Jacobs WW, Jentsch A, Jia J, Jiang K, Jowzaee S, Judd EG, Kabana S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Khan Z, Kikoła DP, Kim C, Kisel I, Kisiel A, Kochenda L, Kocmanek M, Kollegger T, Kosarzewski LK, Kraishan AF, Krauth L, Kravtsov P, Krueger K, Kulathunga N, Kumar L, Kvapil J, Kwasizur JH, Lacey R, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li W, Li Y, Li X, Lidrych J, Lin T, Lisa MA, Liu P, Liu F, Liu H, Liu Y, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo X, Luo S, Ma GL, Ma L, Ma YG, Ma R, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Meehan K, Mei JC, Miller ZW, Minaev NG, Mioduszewski S, Mishra D, Mizuno S, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nasim M, Nayak TK, Nelson JM, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov VA, Olvitt D, Page BS, Pak R, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Pile P, Pluta J, Poniatowska K, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Ramachandran S, Ray RL, Reed R, Rehbein MJ, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roth JD, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Sangaline E, Saur M, Schambach J, Schmah AM, Schmidke WB, Schmitz N, Schweid BR, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma MK, Sharma A, Shen WQ, Shi Z, Shi SS, Shou QY, Sichtermann EP, Sikora R, Simko M, Singha S, Skoby MJ, Smirnov D, Smirnov N, Solyst W, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Strikhanov M, Stringfellow B, Sugiura T, Sumbera M, Summa B, Sun XM, Sun Y, Sun X, Surrow B, Svirida DN, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Tawfik A, Thäder J, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vasiliev AN, Videbæk F, Vokal S, Voloshin SA, Vossen A, Wang F, Wang Y, Wang G, Wang Y, Webb JC, Webb G, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu Z, Xu N, Xu YF, Xu QH, Xu J, Yang Q, Yang C, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang XP, Zhang S, Zhang JB, Zhang J, Zhang Z, Zhang S, Zhang J, Zhang Y, Zhao J, Zhong C, Zhou L, Zhou C, Zhu Z, Zhu X, Zyzak M. Beam Energy Dependence of Jet-Quenching Effects in Au+Au Collisions at sqrt[s_{NN}]=7.7, 11.5, 14.5, 19.6, 27, 39, and 62.4 GeV. PHYSICAL REVIEW LETTERS 2018; 121:032301. [PMID: 30085817 DOI: 10.1103/physrevlett.121.032301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 03/29/2018] [Indexed: 06/08/2023]
Abstract
We report measurements of the nuclear modification factor R_{CP} for charged hadrons as well as identified π^{+(-)}, K^{+(-)}, and p(p[over ¯]) for Au+Au collision energies of sqrt[s_{NN}]=7.7, 11.5, 14.5, 19.6, 27, 39, and 62.4 GeV. We observe a clear high-p_{T} net suppression in central collisions at 62.4 GeV for charged hadrons which evolves smoothly to a large net enhancement at lower energies. This trend is driven by the evolution of the pion spectra but is also very similar for the kaon spectra. While the magnitude of the proton R_{CP} at high p_{T} does depend on the collision energy, neither the proton nor the antiproton R_{CP} at high p_{T} exhibit net suppression at any energy. A study of how the binary collision-scaled high-p_{T} yield evolves with centrality reveals a nonmonotonic shape that is consistent with the idea that jet quenching is increasing faster than the combined phenomena that lead to enhancement.
Collapse
|
17
|
Bartsch N, Girard M, Schneider L, Weijgert VVD, Wilde A, Kappenstein O, Vieth B, Hutzler C, Luch A. Chemical stabilization of polymers: Implications for dermal exposure to additives. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH. PART A, TOXIC/HAZARDOUS SUBSTANCES & ENVIRONMENTAL ENGINEERING 2018; 53:405-420. [PMID: 29334019 DOI: 10.1080/10934529.2017.1412192] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Technical benefits of additives in polymers stand in marked contrast to their associated health risks. Here, a multi-analyte method based on gas chromatography coupled to tandem mass spectrometry (GC-MS/MS) was developed to quantify polymer additives in complex matrices such as low-density polyethylene (LDPE) and isolated human skin layers after dermal exposure ex vivo. That way both technical aspects and dermal exposure were investigated. The effects of polymer additivation on the material were studied using the example of LDPE. To this end, a tailor-made polymer was applied in aging studies that had been furnished with two different mixtures of phenol- and diarylamine-based antioxidants, plasticizers and processing aids. Upon accelerated thermo-oxidative aging of the material, the formation of LDPE degradation products was monitored with attenuated total reflectance-Fourier transformed infrared (ATR-FTIR) spectroscopy. Compared to pure LDPE, a protective effect of added antioxidants could be observed on the integrity of the polymer. Further, thermo-oxidative degradation of the additives and its kinetics were investigated using LDPE or squalane as matrix. The half-lives of additives in both matrices revealed significant differences between the tested additives as well as between LDPE and squalane. For instance, 2-tert-butyl-6-[(3-tert-butyl-2-hydroxy-5-methylphenyl)methyl]-4-methylphenol (Antioxidant 2246) showed a half-life 12 times lower when incorporated in LDPE as compared to squalane. As a model for dermal exposure of consumers, human skin was brought into contact with the tailor-made LDPE containing additives ex vivo in static Franz diffusion cells. The skin was then analyzed for additives and decomposition products. This study proved 10 polymer additives of diverse pysicochemical properties and functionalities to migrate out of the polymer and eventually overcome the intact human skin barrier during contact. Moreover, their individual distribution within distinct skin layers was demonstrated. This is exemplified by the penetration of the procarcinogenic antioxidant N-phenylnaphthalen-2-amine (Neozon D) into the viable epidermis and the permeation through the skin of the neurotoxic plasticizer N-butylbenzenesulfonamide (NBBS). In addition, the analyses of additive degradation products in the isolated skin layers revealed the presence of 2-tert-butyl-4-methylphenol in all layers after contact to a polymer with substances of origin like Antioxidant 2246. Thus, attention needs to be paid to absorption of polymer additives together with their degradation products when it comes to dermal exposure assessment.
Collapse
|
18
|
Girard M, Delanghe M, Domingo-Levy L, Zamith-Chavant M. Cas pratique de communication institutionnelle : la sollicitation des psychologues par les soignants de l’IUCT-O. PSYCHO-ONCOLOGIE 2018. [DOI: 10.3166/pson-2018-0028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
19
|
Girard M. Management of Hypertension. J R Soc Med 2018; 84:572. [PMID: 1941869 PMCID: PMC1293440 DOI: 10.1177/014107689108400936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
20
|
Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Ajitanand NN, Alekseev I, Anderson DM, Aoyama R, Aparin A, Arkhipkin D, Aschenauer EC, Ashraf MU, Attri A, Averichev GS, Bai X, Bairathi V, Barish K, Behera A, Bellwied R, Bhasin A, Bhati AK, Bhattarai P, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Bouchet J, Brandenburg JD, Brandin AV, Brown D, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Campbell JM, Cebra D, Chakaberia I, Chaloupka P, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen X, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Das S, De Silva LC, Dedovich TG, Deng J, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Draper JE, Dunkelberger LE, Dunlop JC, Efimov LG, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Federicova P, Fedorisin J, Feng Z, Filip P, Finch E, Fisyak Y, Flores CE, Fujita J, Fulek L, Gagliardi CA, Garand D, Geurts F, Gibson A, Girard M, Grosnick D, Gunarathne DS, Guo Y, Gupta A, Gupta S, Guryn W, Hamad AI, Hamed A, Harlenderova A, Harris JW, He L, Heppelmann S, Heppelmann S, Hirsch A, Horvat S, Huang X, Huang B, Huang T, Huang HZ, Humanic TJ, Huo P, Igo G, Jacobs WW, Jentsch A, Jia J, Jiang K, Jowzaee S, Judd EG, Kabana S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Khan Z, Kikoła DP, Kim C, Kisel I, Kisiel A, Kochenda L, Kocmanek M, Kollegger T, Kosarzewski LK, Kraishan AF, Krauth L, Kravtsov P, Krueger K, Kulathunga N, Kumar L, Kvapil J, Kwasizur JH, Lacey R, Landgraf JM, Landry KD, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li X, Li Y, Li W, Lidrych J, Lin T, Lisa MA, Liu P, Liu H, Liu Y, Liu F, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo S, Luo X, Ma YG, Ma L, Ma R, Ma GL, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Meehan K, Mei JC, Miller ZW, Minaev NG, Mioduszewski S, Mishra D, Mizuno S, Mohanty B, Mondal MM, Morozov DA, Mustafa MK, Nasim M, Nayak TK, Nelson JM, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Nurushev SB, Odyniec G, Ogawa A, Oh K, Okorokov VA, Olvitt D, Page BS, Pak R, Pandit Y, Panebratsev Y, Pawlik B, Pei H, Perkins C, Pile P, Pluta J, Poniatowska K, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Ramachandran S, Ray RL, Reed R, Rehbein MJ, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Roth JD, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Saur M, Schambach J, Schmah AM, Schmidke WB, Schmitz N, Schweid BR, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sharma A, Sharma MK, Shen WQ, Shi SS, Shi Z, Shou QY, Sichtermann EP, Sikora R, Simko M, Singha S, Skoby MJ, Smirnov N, Smirnov D, Solyst W, Song L, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Strikhanov M, Stringfellow B, Suaide AAP, Sugiura T, Sumbera M, Summa B, Sun Y, Sun XM, Sun X, Surrow B, Svirida DN, Tang Z, Tang AH, Taranenko A, Tarnowsky T, Tawfik A, Thäder J, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Trzeciak BA, Tsai OD, Ullrich T, Underwood DG, Upsal I, Van Buren G, van Nieuwenhuizen G, Vasiliev AN, Videbæk F, Vokal S, Voloshin SA, Vossen A, Wang G, Wang Y, Wang F, Wang Y, Webb JC, Webb G, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu J, Xu Z, Xu QH, Xu YF, Xu N, Yang S, Yang Y, Yang C, Yang Q, Ye Z, Ye Z, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang Z, Zhang JB, Zhang J, Zhang S, Zhang Y, Zhang XP, Zhang J, Zhang S, Zhao J, Zhong C, Zhou C, Zhou L, Zhu X, Zhu Z, Zyzak M. Beam-Energy Dependence of Directed Flow of Λ, Λ[over ¯], K^{±}, K_{s}^{0}, and ϕ in Au+Au Collisions. PHYSICAL REVIEW LETTERS 2018; 120:062301. [PMID: 29481217 DOI: 10.1103/physrevlett.120.062301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Indexed: 06/08/2023]
Abstract
Rapidity-odd directed-flow measurements at midrapidity are presented for Λ, Λ[over ¯], K^{±}, K_{s}^{0}, and ϕ at sqrt[s_{NN}]=7.7, 11.5, 14.5, 19.6, 27, 39, 62.4, and 200 GeV in Au+Au collisions recorded by the Solenoidal Tracker detector at the Relativistic Heavy Ion Collider. These measurements greatly expand the scope of data available to constrain models with differing prescriptions for the equation of state of quantum chromodynamics. Results show good sensitivity for testing a picture where flow is assumed to be imposed before hadron formation and the observed particles are assumed to form via coalescence of constituent quarks. The pattern of departure from a coalescence-inspired sum rule can be a valuable new tool for probing the collision dynamics.
Collapse
|
21
|
Armiroli S, Cotillard R, Laffont G, Girard M, Cambet D, Jeannot JP, Charvet P, Albaladéjo S, Lusso S. Optical fiber distributed sensing based on Rayleigh scatter frequency domain reflectometry for Sodium leakage detection within SFR reactors. EPJ WEB OF CONFERENCES 2018. [DOI: 10.1051/epjconf/201817003001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Ruppé E, Cherkaoui A, Wagner N, La Scala GC, Beaulieu JY, Girard M, Frey J, Lazarevic V, Schrenzel J. In vivo selection of a multidrug-resistant Aeromonas salmonicida during medicinal leech therapy. New Microbes New Infect 2017; 21:23-27. [PMID: 29204282 PMCID: PMC5709350 DOI: 10.1016/j.nmni.2017.10.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2017] [Revised: 09/15/2017] [Accepted: 10/04/2017] [Indexed: 12/18/2022] Open
Abstract
We report the selection in a 15-year-old boy of a multidrug-resistant, extended-spectrum β-lactamase (ESBL)-producing Aeromonas salmonicida after medicinal leech therapy that required an antibiotic prophylaxis based on piperacillin/tazobactam and cotrimoxazole. Whole genome sequencing of the strain indeed revealed 13 antibiotic resistance genes, including the ESBL CTX-M-3 and the unusual β-lactamase SCO-1.
Collapse
|
23
|
Girard M, Marchand F, Uch R, Bretelle F. [Trauma and pregnancy: Is the Kleihauer-Betke test really useful?]. ACTA ACUST UNITED AC 2017; 45:584-589. [PMID: 28967599 DOI: 10.1016/j.gofs.2017.08.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2017] [Accepted: 08/29/2017] [Indexed: 10/18/2022]
Abstract
OBJECTIVE To evaluate the pertinence of Kleihauer-Betke (KB) test, in case of abdominal trauma during pregnancy in forecast of fetal outcomes, according to trauma severity. METHODS A single-center retrospective study conducted between January 2014 and April 2016 in a maternity type III and a trauma center, which included the pregnant women admitted for abdominal trauma. The trauma's severity was assessed using the guidelines of the Society of Obstetricians and Gynaecologists of Canada. The impact of a positive KB test, defined as>0.1%, was analyzed. Adverse outcome was defined as one or more of the following complications: intrauterine fetal death, placental abruption, pre-term birth<37 weeks of gestation, and fetal or neonatal anemia. RESULTS During the study period, 265 pregnancies involved into an abdominal trauma were included: 69% with a minor trauma and 31% with a severe trauma. Of all patients, 5.6% presented a positive KB test, among then 15.4% had an adverse outcome. There was no significant difference in the rate of adverse outcomes in the positive KB group and the KB negative group either in the overall population (P=0.16), in the minor trauma population (P=1) or in the major trauma population (P=0.14). The predictive positive values were respectively in the global population, in the minor trauma group and in the severe trauma group 15.4%, 0% and 25%. CONCLUSIONS The KB test does not seem to be useful in case of trauma during pregnancy to define adverse outcome.
Collapse
|
24
|
Traboulsee A, Machan L, Girard M, Raymond J, Vosoughi R, Hardy B, Edmond F, Bone J, Gariepy J, Tam R, Klass D, Isserow S, Rauscher A, Sadovnick A, Li D, Illes J, Siskin G. Venoplasty of chronic cerebral spinal venous insufficiency to improve MS patient reported outcomes is not superior to sham treatment at week 2 or week 12. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Brisson H, Arbelot C, Monsel A, Parisot C, Girard M, Savier E, Vezinet C, Lu Q, Vaillant JC, Golmard JL, Gorochov G, Langeron O, Rouby JJ. Impact of graft preservation solutions for liver transplantation on early cytokine release and postoperative organ dysfunctions. A pilot study. Clin Res Hepatol Gastroenterol 2017; 41:564-574. [PMID: 28330599 DOI: 10.1016/j.clinre.2016.12.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 12/23/2016] [Accepted: 12/28/2016] [Indexed: 02/06/2023]
Abstract
INTRODUCTION During liver transplantation, graft ischemia-reperfusion injury leads to a systemic inflammatory response producing postoperative organ dysfunctions. The aim of this observational and prospective study was to compare the impact of Solution de conservation des organes et tissus (SCOT) 15 and University of Wisconsin (UW) preservation solutions on early cytokine release, postreperfusion syndrome and postoperative organ dysfunctions. METHODS Thirty-seven liver transplantations were included: 21 in UW Group and 16 in SCOT 15 group. Five cytokines were measured in systemic blood after anesthetic induction, 30minutes after unclamping portal vein and on postoperative day 1. RESULTS Following unclamping portal vein, cytokines were released in systemic circulation. Systemic cytokine concentrations were higher in UW than in SCOT 15 group: Interleukin-10, Interleukine-6. In SCOT 15 group, significant reduction of postreperfusion syndrome incidence and acute kidney injury were observed. Alanine and aspartate aminotransferase peak concentrations were higher in SCOT 15 group than in UW group. However, from postoperative day 1 to day 10, aminotransferase returned to normal values and did not differ between groups. CONCLUSIONS Compared to UW, SCOT 15 decreases systemic cytokine release resulting from graft ischemia-reperfusion injury and reduces incidence of postreperfusion syndrome and postoperative renal failure.
Collapse
|